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The deubiquitinating enzymeUSP7 is an emerging oncology and antiviral target. Reverdy et al., in this issue of
Chemistry & Biology, disclose the first small-molecule inhibitor selective for USP7, which recapitulates its
knockdown in cancer cells and hence demonstrates the therapeutic feasibility of USP7 inhibitors.Covalent modification of cellular proteins
by ubiquitin (Ub) represents a highly
versatile posttranslational mechanism
that underpins proteasomal degradation
and regulates a diverse array of cellular
processes (Komander et al., 2009;
Reyes-Turcu et al., 2009). Defects in ubiq-
uitin-based control mechanisms have
been implicated in the pathogenesis of
numerous disease states including
cancer, chronic diseases, and viral infec-
tions (Lindner, 2007; Singhal et al.,
2008). Hence, components of the ubiqui-
tin system emerge as attractive drug
targets, reinforced by the approval of
the proteasome inhibitor Velcade in
oncology. Protein ubiquitination is a
dynamic and reversible process con-
trolled by the coordinated action of
multiple ubiquitin-conjugating and deubi-
quitinating enzymes (DUBs). The human
genome contains nearly 100 DUBs, which
can be divided in five structural classes.
USP7, which is the enzyme targeted for
inhibitor discovery by Colland and co-
workers (Reverdy et al., 2012), is part of
the ubiquitin-specific proteases (USP)
class, a group of cysteine proteases
comprising approximately 60 members.
Several studies have linked USP7 to
diseases, particularly cancer, and the
enzyme is considered a very promisingtarget for drug discovery (Nicholson and
Suresh Kumar, 2011).
A major hurdle in the discovery of
inhibitors for cysteine proteases having
the papain-like fold is achieving inhibi-
tory selectivity. This is due to relatively
shallow substrate-binding sites lined
with residues well conserved over large
families of homologous enzymes. More-
over, high-throughput screening (HTS)
hits have acceptable inhibitory potency
but often do not display the desired level
of selectivity, requiring further optimiza-
tion. Nonetheless, HTS campaigns have
led to several active site-directed small-
molecule USP inhibitors. A cyano-indeno-
pyrazine derivative (HBX 41,108) was
disclosed as a reversible uncompetitive
low mM inhibitor of human USP7 of
modest selectivity against several DUBs
and other cysteine proteases (Colland
et al., 2009; Reverdy et al., 2012). Another
compound was found to inhibit the
proteaseome-activated form of human
USP14 in mM range but to inhibit IsoT
(human USP5) only 20-fold weaker (Lee
et al., 2010). Several structurally unrelated
inhibitors of human USP1 were discov-
ered in mM range but inhibited at least
one other human USP with similar poten-
cies (Chen et al., 2011). Other recent
efforts in the field have lead to com-pounds with often limited assessment
of selectivity. Perhaps the most success-
ful selective inhibition of a USP was
achieved for the PLpro of the SARS coro-
navirus. Small-molecule, non-covalent,
substrate-binding-site-directed inhibitors
of this viral USP were discovered in the
mM range potency and with excellent
selectivity profile (Ratia et al., 2008). This
high selectivity was likely afforded by the
relative divergence of the viral USP from
human USPs both structurally and func-
tionally. In all these cases, the inhibitors
were tested against a very limited set of
USPs or DUBs.
In this issue of Chemistry & Biology,
Reverdy et al. (2012) report 9-chloro
derivatives of amidotetrahydroacridine
as USP7 inhibitors in the mM range,
identified from an in vitro enzymatic
HTS. Importantly, these compounds
show good selectivity for USP7 when
tested against other human USPs and
DUBs. An interesting and commendable
aspect is the use of an activity-based
molecular probe (HAUbVS) that can label
active cellular USPs, giving access to
a large repertoire of USPs therefore
permitting a thorough evaluation of
inhibitory selectivity. The selectivity data
obtained in vitro on cell lysates using
HAUbVS indicate that the inhibitor (HBXª2012 Elsevier Ltd All rights reserved 437
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Previews19,818) reduced USP7 labeling but not
labeling of other active USPs endoge-
nously expressed under physiological
conditions. Moreover, the inhibitor specif-
ically hits the USP7 target in living cells, as
it disrupted HAUbVS competitive labeling
of USP7 without any off-target activity
across several different endogenous
deubiquitinating activities. In cancer cells,
several effects of the inhibitor were
monitored aiming to recapitulate USP7
silencing. These included compromised
UV-induced Chk1 phosphorylation and
decreased levels of checkpoint mediator
Claspin, modulation of endogenous
levels of additional USP7 substrates
such as Mdm2 and p53, with observed
destabilization of Mdm2. Additionally,
the USP7 inhibitor reduced cell prolifera-
tion, induced caspase activity and PARP
cleavage, and arrested colon cancer cells
in G1. All these results strongly suggest
that the discovered compound displays
an appreciable level of potency and
selectivity toward USP7.
An irreversible active-site-directed inhi-
bition mechanism was proposed based
on mass spectrometry experiments, with
a covalent bond formed with the catalytic
Cys223 of USP7. Interestingly, the mass
difference of 36 Da lost during covalent
inhibition is consistent with displacement
of the 9-Cl substituent by the active site
thiolate. This proposed inhibition mecha-
nism is unusual in that it has not been
exploited in the field of cysteine protease
inhibition so far. An aromatic chlorine acti-
vated by the tetrahydroacridine system
may render this mechanism possible.
Molecular docking of the inhibitor posi-438 Chemistry & Biology 19, April 20, 2012 ªtions the Cl substituent in the proximity
of the active site Cys, in agreement with
the proposed mechanism, while a
required positively charged amine sub-
stituent interacts with negatively charged
residues. Intriguingly, the authors specu-
late that inhibition may actually occur in
the inactive state of USP7 featuring a
misaligned catalytic triad. The relatively
limited number of USP structures solved
to date show that substrate-induced
conformational changes involve mostly
loop movements, while the catalytic
triad misalignment was confirmed only
for USP7. Therefore, these compounds
might indeed exploit a unique structural
feature of USP7 for achieving selectivity.
Structure determination of the enzyme-
inhibitor complex complemented by
structure-function studies are needed to
confirm this and other mechanistic
hypotheses. It would be interesting to
see whether the reactivity of the Cl sub-
stituent can be optimized, since some
weak labeling of another, solvent-ex-
posed, Cys residue of USP7 was also
noted.
The inhibitor discovery and character-
ization described by Reverdy et al.
(2012) provides general proof-of-principle
that selective small-molecule inhibitors
can be identified for an enzyme family
like USPs. This is a significant achieve-
ment, considering that it concentrates
on the active site region perceived as
intractable for achieving inhibitory selec-
tivity. Due to the participation of USPs
in complex protein networks with multiple
biological functions, the tremendous
possibility of off-target effects cannot be2012 Elsevier Ltd All rights reservedoverlooked. The route from an inhibitor
to a drug is certainly not trivial, and one
cannot predict if the compounds will
display a good safety profile. However,
identification of inhibitors that bind selec-
tively to USP7 and modulate steady-state
levels of its substrates can be viewed as
a step in the right direction and opens an
exciting avenue toward potential thera-
peutic interventions.REFERENCES
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